Breast Lesion Localization Methods Market worth $305 million by 2026 – Exclusive Report by MarketsandMarkets™

Breast Lesion Localization Methods Marketby Type (Wire, Radioisotope (ROLL, RSL), Magnetic, Electromagnetic Localization), Usage (Breast Biopsy, Lumpectomy), End User Preference Survey (Selection Criteria, Replacement Trend) (2022 – 2026) according to a new report by MarketsandMarkets. The breast lesion localization market is expected to reach USD 305 million by 2026 from USD 244 million in 2021, will grow at a CAGR of 4.6% during the forecast period. The market is primarily driven by the increasing number of breast cancer screening programs, and improved reimbursement scenario. The localization of breast lesions is a common procedure that has evolved as a surgical, imaging, and biomedical technology. Wire guided localization method was introduced years ago and was the first technique introduced to help localize non-palpable image-guided breast lesions.

Download PDF Brochure:

Breast Lesion Localization market Dynamics

Drivers: Increasing incidence of breast cancer

Breast cancer is among the most common diseases affecting women in developed and developing countries. According to the American Cancer Society, breast cancer is the second-leading cause of cancer-related deaths in women across the globe. Globally, there has been significant growth in the number of breast cancer cases. This can majorly be attributed to changing lifestyles, the increasing use of oral contraceptives, and the growing number of women undergoing cosmetic surgeries, such as breast enhancement.

Growing rate of the aging population

With age, the risk of developing breast cancer increases. Aging increases multipotent progenitors (a type of adult stem cell at the root of many breast cancers) and decreases the number of myoepithelial cells, which line the breast’s milk-producing luminal cells and serve as tumor suppressors. According to the American Cancer Society, approximately 1 out of 8 invasive breast cancers develop in women less than 45 years. In contrast, approximately 2 out of 3 invasive breast cancers develop in women aged 55 and above.

Restraints: Uncertainty in regulatory approval procedures

Regulatory agencies such as the US FDA require comprehensive clinical data supporting the clinical safety and efficacy of a product under approval. With the presence of stringent regulatory requirements for product approval, players operating in the breast lesion localization methods (specially radioisotope localization) market need to obtain nuclear regulatory clearance from the Nuclear Regulatory Commission to ensure the safe use of radioactive seeds. This approval process is very lengthy and capital-intensive, which makes it difficult for small manufacturers and companies with limited budgets to sustain themselves in this market.

Opportunities: Emerging economies offer high growth potential

Developing economies, such as India, China, Brazil, South Korea, Turkey, Russia, and South Africa, offer high growth opportunities for the major players operating in the breast lesion localization market. A large population base—especially in India and China—offers a sustainable market for entire medical and surgical devices. As per GLOBOCAN 2020, the incidence of breast cancer in China is estimated to be 416,000 in 2020; this number is estimated to increase by 446,000 cases by 2025. Likewise, the number of women diagnosed with breast cancer is estimated to reach 272,000 in 2040 from 178,000 in 2020 in India. Breast cancer incidence among women aged more than 65 is expected to increase by ~61% and ~65% in India and China, respectively, by 2025.

Governments in emerging countries are also investing heavily in the development and modernization of healthcare infrastructure. For instance, According to the OECD Data, the healthcare spending of China in 2020 was 810.8 USD/Capita. Likewise, according to Health Expenditure and Financing data, Brazil spent ~9.5% of its GDP on healthcare in 2020. The Ministry of Health in Brazil and several non-governmental organizations have also initiated efforts to improve early diagnosis and to promote breast cancer screening and education in the country.

Request Sample Pages:

North America is expected to account for the largest share of the Breast lesion localization market in 2020

In terms of volume, North America accounted for the largest share of the breast lesion localization market is 2020, followed by Europe. The APAC market is projected to grow at the highest CAGR during the forecast period. Growth in this market can primarily be attributed to the improving healthcare infrastructure, rising government spending on breast cancer research, and increasing awareness about the importance of the early detection of breast cancer in several APAC countries.

Key Player

Key Market Players breast lesion localization market are Hologic, Inc. (US), Becton, Dickinson and Company (US), Merit Medical Systems (US), Leica Biosystems Nussloch GmbH (US), Argon Medical Devices (US), Laurane Medical LLC (France), Endomagnetics Ltd. (UK), Intramedical Imaging, LLC (US), Isoaid (US), Surgiceye GmbH (Germany), Ranfac Corp. (US), Mermaid Medical Group (Denmark), Izi Medical Products, LLC (US), Matek Medikal (Turkey), Tsunami Medical Srl (Italy), BPB Medica (Italy), Sirius Medical Systems B.V. (Netherlands), Molli Surgical Inc. (Canada). Other players in the market are Sterylab S.R.L. (Italy), CP Medical (Georgia), MDL SRL (Italy), Biomedical Srl (Italy), Elucent Medical (US), Vigeo srl (Italy), and Medax Medical Devices (Italy).

Get 10% Free Customization on this Report:

Browse Adjacent Market: 3D Bioprinting Market Research Reports & Consulting

Related Reports:

Industrial Evaporators Market by Construction Type (Shell & Tube, Plate), End-use Industry (Food & Beverage, Pharmaceutical, Chemical & Petrochemical, Automotive), Functionality (Falling Film, Rising Film) & Region – Global Forecast to 2027

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their pain points around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 Micro Quadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledge Store” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Mr. Aashish Mehra
MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA: +1-888-600-6441


Visit Our Website:

Content Source: